Advertisement
Advertisement
Beam Therapeutics Inc. (BEAM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 69.08 |
| Open | 68.31 |
| Bid | 70.23 x 800 |
| Ask | 70.31 x 1300 |
| Day's Range | 66.57 - 70.98 |
| 52 Week Range | 27.77 - 116.91 |
| Volume | |
| Avg. Volume | 1,318,790 |
| Market Cap | 4.791B |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Even after rising 8.2% this past week, Beam Therapeutics (NASDAQ:BEAM) shareholders are still down 40% over the past year
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders will doubtless be very grateful to see the share price up 78% in...
- American City Business Journals
Mixed signals: Biotech executives face conflicting signs on growth
Faced with conflicting signs from all sides of the biotech economy, executives are left sorting out how to plan for growth.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
